

Notice of liability:

Vaccination stop based on PEI safety report dated 20.09.2021 in accordance with the [Nuremberg Code](#)

'We for Humanity' is an initiative founded by a group of Holocaust survivors and their descendants. From historical experience we warn: It is the end of any pluralistic democratic society when medicine, science, justice, culture and media subordinate themselves to the dictates of the political executive and of the greed for profit. This is how it comes that the following disturbing facts are withheld from the broad public.

From the [safety report of the Paul Ehrlich Institute \(PEI\) of 20.09.2021](#), which covers the reporting period until 31.08.2021, it appears that more minors are affected by side effects of the Covid-19 "vaccinations" than by SARS-CoV-2 infections.

The 12- to 17-year-olds dually "vaccinated" by Aug. 31, 2021, account for **675,000**, or about **4.91%** of all minors. According to the PEI report, **1,228** children and adolescents suffered adverse events, including three deaths. Among other things, the report points to cases of heart disease - myo/pericarditis - with the highest reporting rate in male adolescents aged 12 to 17 years, followed by young men aged 18 to 29 years.

This compares with **1,225** of **13,743,944** children and adolescents hospitalized with suspected Covid, according to the RKI.

Extrapolated to all adolescents, the number of adverse events is at least **20-fold** higher than Covid hospitalizations. The ratio changes dramatically when one considers that approval of gene therapy is sought for children under 12, and that the reporting rate is less than 1% according to the [Lazarus report](#). Here quoted:

*"Adverse effects with medicines and vaccines are frequent, are however too rarely reported.
... Likewise, less than 1% of the adverse effects of vaccines are reported."*

How many children with "vaccine" injuries have been added since 8/31/21? Have more children died? Can you in good conscience maintain recommendation to subject children and adolescents to experimental gene therapy despite the medically known risks and side effects? Do you have children, grandchildren or godchildren? They could be affected, too.

As you know, the injections are not really vaccines, but gene therapies. Attached are three slides from the May 18, 2021, Genetic Vaccine Development for Infectious Diseases event. The summit was held five months after the global "vaccination campaign" began; speakers found a forum to "*share unpublished data on genetically engineered vaccines*" and "*clinical trial updates for pregnant women*", to name just two topics.

Also, [EU Directive 2009/120/EC](#) states in point 2.1: "*Gene therapy medicinal products shall not include vaccines against infectious diseases.*"

If experimental gene therapy were not mislabeled as "vaccination," a large majority would not subject themselves or their children to these experimental gene therapies. By this mislabeling alone, you have deprived people of an important basis for informed consent. By not providing informed consent, parents are deprived of the freedom to protect their children and themselves from serious physical harm and even death.

To that extent, all ten principles of the Nuremberg Code are violated. As a reminder, read the last sentence of the first principle: All involved are personally liable.

Stop the vaccination program, do not risk another life, check the facts in an open discourse. In any case, you cannot plead ignorance, which could take away the premeditation of a deed.

We for Humanity
trust-in-humanity@pm.me

PS: Here for your attention is our appeal to the European Medicines Agency (EMA) dated 25.08.2021
<https://we-for-humanity.org>

References:

<https://dg-pflegewissenschaft.de/wp-content/uploads/2017/05/NuernbergKodex.pdf>
https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-31-08-21.pdf?__blob=publicationFile&v=5
<https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Jul_2021/2021-07-16-de.pdf?__blob=publicationFile
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-09-02.pdf?__blob=publicationFile
<https://de.rt.com/meinung/124452-mehr-kinder-mit-impfreaktionen-als-mit-covid-im-krankenhaus/>
<https://de.statista.com/statistik/daten/studie/1174053/umfrage/minderjaehrige-in-deutschland-nach-altersgruppen/>
<https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L:2009:242:FULL&from=EN>

Pre-Conference Symposium: SARS-CoV-2

By May, millions of doses of SARS-CoV-2 vaccines will have been administered. We have curated a tailored and focused program specifically on the SARS-CoV-2 pathogen to bring you updates on safety and effectiveness, correlates of protection, duration of long-term immunity, and use in potentially at-risk population groups such as pregnant women, children, and allergy sufferers.

Tuesday, May 18 (AM)	Tuesday, May 18 (PM)
9:00 Update on Clinical Trials Involving Pregnant Women with COVID-19 Vaccines	12:00 IND-4800 – A DNA based Vaccine Against COVID-19
9:30 Controlled Human Infection Models to Further Validate the Efficacy of COVID-19 Vaccines	12:30 CVnCov: CureVac's mRNA-based Vaccine Candidate Against COVID-19
10:00 Development of an mRNA-based COVID-19 Vaccine at 'lightspeed': From Pre-Clinical Studies to Large-scale Manufacture	2:00 Immunogenicity of Chimpanzee Adenovirus Vector Vaccines Expressing SARS-CoV2 Spike and Nucleocapsid
10:30 Moderna's COVID-19 Vaccine: A Summary of Available Clinical Data	2:30 Development of AAVCOVID: A Single Dose AAV-based Vaccine for COVID-19
11:30 Clinical and Operational Challenges of COVID-19 Vaccine Development and Future Opportunities	3:00 A Framework to Analyse the Pandemic Potential of Pathogens: COVID-19 and Future Directions

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

The 3-day case study-led program will bring together a wealth of knowledge into the complexities of the new and emerging field of gene-based vaccines, bringing together both pioneering academics and non-profit institutions, and leading biotech and pharma. Expect to hear updates on long-term clinical efficacy and safety, immune responses, novel delivery methods, and genetic platforms.

Attend this event to:



Understand how the optimization of lipid nanoparticles allows for efficient and safe delivery of mRNA

Hear **Moderna** speak on the use of their mRNA technology platform for the development of mRNA-based vaccines, and a case study on mRNA-1273, one of the first approved COVID-19 vaccines



Learn the critical steps in mRNA vaccine development that allowed for the 'lightspeed' deployment of a SARS-CoV-2 vaccine

From pre-clinical studies to large-scale manufacture, **BioNTech** will be sharing how they went about developing the first COVID-19 vaccine, as well as sharing pre-clinical data on wider infectious disease programs



Optimizing next-generation vaccine development and lessons learned from COVID-19

Take part in an interactive panel discussion with **Pfizer** to learn how new vaccine technologies can stave off future outbreaks, and how the future of vaccine development has been changed by COVID-19



Discover the latest updates in DNA-based vaccines against infectious diseases

Hear **INOVIQ** speak on efficacy in animal challenge models, thermo-stability of DNA vaccines, and clinical immunogenicity and safety profiling of INO-4800 in the race to be the first approved DNA vaccine for human use



Clinical and operational challenges of COVID-19 vaccine development and future opportunities

Understand how defining clinical trial endpoints for a new pathogen with limited pre-existing evidence can be overcome, why we need correlates of protection, and how to establish vaccine efficacy when placebo-controlled trials become more difficult

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

Overcome the Translational Challenges of Developing mRNA, DNA & Engineered Viral Vector-Based Vaccines

The **Genetic Vaccine Development for Infectious Diseases Summit** will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases.

The agenda will cover clinical trial updates for pregnant women on COVID-19 candidates and long-term correlates of protection, plus our expert speakers will share *unpublished data* on gene-based vaccines for a wide range of infectious diseases, including **Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19**.

With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:



Progress your own expertise and forge powerful collaborations with leading biotech, pharma, academics & NPOs



Overcome immunogenicity challenges to design safe and efficacious vaccine formulations



Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for public use

Form Powerful Collaborations with Pioneering Biopharma

The digital **Genetic Vaccine Development for Infectious Diseases Summit** is not only the first, but the *only* industry-dedicated meeting that brings you the most up-to-date clinical and commercial developments utilizing next-generation vaccine technologies for infectious diseases.

Join 100+ experts online from companies such as **BioNTech, Pfizer, Moderna, AstraZeneca, CureVac** and more to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology.